Inspiration
In the BioHacks case, Alex Chen wants to keep teaching and cooking as ALS makes everyday movements harder. We wanted to explore a treatment that could help preserve the motor neurons he still relies on. We also wanted to investigate whether an injection under the skin could eventually reduce the burden of repeated spinal taps.
What it does
SpliceBridge is an interactive pitch and research proposal for delivering an RNA repair drug to spinal motor neurons. We propose linking a splice-correcting antisense oligonucleotide (ASO) to an antibody that binds transferrin receptor 1 (TfR1). The antibody is designed to help carry the ASO across the blood vessel barrier. Inside a motor neuron, the ASO would bind STMN2 RNA and help the cell produce the full-length message for stathmin-2, a protein involved in axon repair.
How we built it
We built the pitch in HTML, CSS, and JavaScript. The animation follows the proposed drug from injection to the motor neuron nucleus. The site also walks through our first experiment, the safety and access questions we’d need to answer, and what preserving motor function could mean for Alex.
Challenges we ran into
The hardest part was defining what would count as successful delivery. A drug can cross a barrier and still miss the cells it needs to reach. In one mouse study, a related carrier accumulated mainly in spinal support cells, with little signal in motor neurons. That finding shaped our proposed experiment. Spinal cell distribution study
We designed a comparison using a human barrier model with spinal motor neurons on the far side. We’d compare the free ASO, our TfR1-linked ASO, and the same ASO attached to a matched carrier that cannot bind TfR1. Our first sign of success would be more full-length STMN2 RNA inside identified motor neurons, with the barrier intact and the cells healthy. We built the pitch and designed the experiment during BioHacks. Lab testing would be the next step.
Accomplishments that we're proud of
We turned a question from Alex’s case into a testable research proposal. The part we’re proudest of is defining what successful delivery would look like. An RNA drug could cross the barrier and still miss the cells it needs to reach. We designed an experiment that asks whether our antibody carrier helps spinal motor neurons make more full-length STMN2 RNA than they would with the free drug or a carrier that cannot bind TfR1. We also built an interactive pitch that follows the proposed drug from injection to the motor neuron nucleus. The animation helped us explain why each step matters and show where the design could fail, while keeping Alex’s goals of teaching and cooking at the center.
What we learned
Published experiments showed that correcting STMN2 RNA improved axon regrowth in lab-grown human motor neurons. A separate animal study showed that a TfR1 carrier could deliver a different active ASO into neurons. Together, those findings gave us a reason to investigate the approach. Whether our carrier can deliver enough active STMN2 ASO to spinal motor neurons remains an open question.
What's next for SpliceBridge
Our next step is to work with a research lab to test the carrier in a human cell model of the blood–spinal cord barrier. We’d compare our TfR1-linked drug with the free drug and a matched carrier that can’t bind TfR1. We’d measure how much intact drug crosses the barrier and whether the motor neurons on the other side make more full-length STMN2 RNA. If the drug crosses but the RNA stays unchanged, we’d check whether it reaches the motor neurons and remains active after being linked to the carrier. If we see RNA correction, we’d test whether it improves axon repair. A later animal study would ask how much intact drug reaches the bloodstream after an injection under the skin, where it goes, and whether repeated doses are tolerated.
Built With
- css
- graphics
- html
- javascript